| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2014PNAS..11110732S |
| P356 | DOI | 10.1073/PNAS.1321785111 |
| P932 | PMC publication ID | 4115570 |
| P698 | PubMed publication ID | 25002524 |
| P5875 | ResearchGate publication ID | 264643573 |
| P50 | author | Jacob I Ayers | Q57000709 |
| P2093 | author name string | Benoit I Giasson | |
| Todd E Golde | |||
| David R Borchelt | |||
| Lucia Notterpek | |||
| Michael A Thomas | |||
| Robert W Regenhardt | |||
| Sooyeon Lee | |||
| Alex B McKinney | |||
| Amanda N Sacino | |||
| Mieu Brooks | |||
| Nicholas H McGarvey | |||
| P2860 | cites work | Thinking laterally about neurodegenerative proteinopathies | Q36793466 |
| A novel α-synuclein missense mutation in Parkinson disease | Q36841475 | ||
| Amyloidogenic α-synuclein seeds do not invariably induce rapid, widespread pathology in mice | Q36907399 | ||
| α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? | Q36925651 | ||
| Characterization of antibodies that selectively detect alpha-synuclein in pathological inclusions | Q37148311 | ||
| Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation | Q37293239 | ||
| Molecular mechanisms of alpha-synuclein neurodegeneration | Q37309838 | ||
| Transmission of multiple system atrophy prions to transgenic mice | Q37353012 | ||
| Mendelian forms of Parkinson's disease | Q37376999 | ||
| Characterization of hydrophobic residue requirements for alpha-synuclein fibrillization | Q37378632 | ||
| Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells | Q37446544 | ||
| Induction of CNS α-synuclein pathology by fibrillar and non-amyloidogenic recombinant α-synuclein | Q37484884 | ||
| Involvement of the peripheral nervous system in synucleinopathies, tauopathies and other neurodegenerative proteinopathies of the brain | Q37763622 | ||
| Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation | Q40964871 | ||
| Conformational templating of α-synuclein aggregates in neuronal-glial cultures | Q41494001 | ||
| Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia. | Q41997706 | ||
| Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology | Q42487446 | ||
| Peripheral administration of tau aggregates triggers intracerebral tauopathy in transgenic mice | Q42874098 | ||
| Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease | Q43144355 | ||
| Molecular determinants of the aggregation behavior of alpha- and beta-synuclein | Q43157334 | ||
| Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys. | Q46970748 | ||
| Morphogenesis of Lewy bodies: dissimilar incorporation of alpha-synuclein, ubiquitin, and p62. | Q47300849 | ||
| Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease | Q48353748 | ||
| Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein | Q48581887 | ||
| Prion-like acceleration of a synucleinopathy in a transgenic mouse model | Q48965892 | ||
| A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly | Q54031652 | ||
| Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro | Q64865343 | ||
| Pathogenesis of scrapie is faster when infection is intraspinal instead of intracerebral | Q67244840 | ||
| Self-propagation of pathogenic protein aggregates in neurodegenerative diseases | Q26996441 | ||
| Mutation in the alpha-synuclein gene identified in families with Parkinson's disease | Q27860459 | ||
| alpha-Synuclein locus triplication causes Parkinson's disease | Q27860533 | ||
| Staging of brain pathology related to sporadic Parkinson's disease | Q28131702 | ||
| Alpha-synuclein and neurodegenerative diseases | Q28204386 | ||
| Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications | Q28241852 | ||
| Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease | Q28275257 | ||
| Prominent Perikaryal Expression of α- and β-Synuclein in Neurons of Dorsal Root Ganglion and in Medullary Neurons | Q28570621 | ||
| Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system | Q28594502 | ||
| The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia | Q29547174 | ||
| AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease | Q29547175 | ||
| Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation | Q29615640 | ||
| Pathological α-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice | Q29620597 | ||
| Animal models of PD: pieces of the same puzzle? | Q33337447 | ||
| Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia | Q33874305 | ||
| A novel, high-efficiency cellular model of fibrillar alpha-synuclein inclusions and the examination of mutations that inhibit amyloid formation | Q34010946 | ||
| Age-dependent synuclein pathology following traumatic brain injury in mice | Q34278990 | ||
| Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein | Q34294957 | ||
| The biochemistry of Parkinson's disease | Q34426026 | ||
| Triggering of inflammasome by aggregated α-synuclein, an inflammatory response in synucleinopathies | Q34576478 | ||
| Transfer of human α-synuclein from the olfactory bulb to interconnected brain regions in mice | Q34909750 | ||
| Induction of Intracellular Tau Aggregation Is Promoted by α-Synuclein Seeds and Provides Novel Insights into the Hyperphosphorylation of Tau | Q35065979 | ||
| Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen | Q35117445 | ||
| E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment | Q35266392 | ||
| Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis | Q35601755 | ||
| Prion-like spread of protein aggregates in neurodegeneration | Q35946138 | ||
| Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice | Q35946149 | ||
| Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered | Q36641009 | ||
| Prion-like spreading of pathological α-synuclein in brain | Q36732844 | ||
| P433 | issue | 29 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pathology | Q7208 |
| phenotype | Q104053 | ||
| Synuclein | Q24767155 | ||
| P1104 | number of pages | 6 | |
| P304 | page(s) | 10732-10737 | |
| P577 | publication date | 2014-07-07 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Intramuscular injection of α-synuclein induces CNS α-synuclein pathology and a rapid-onset motor phenotype in transgenic mice | |
| P478 | volume | 111 |
| Q47995205 | 'Prion-like' propagation of the synucleinopathy of M83 transgenic mice depends on the mouse genotype and type of inoculum |
| Q58598324 | A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein |
| Q48342883 | A critical review of the prion hypothesis of human synucleinopathies |
| Q41069719 | A novel panel of α-synuclein antibodies reveal distinctive staining profiles in synucleinopathies. |
| Q36148314 | Activation of MyD88-dependent TLR1/2 signaling by misfolded α-synuclein, a protein linked to neurodegenerative disorders |
| Q55496331 | Activity of translation regulator eukaryotic elongation factor-2 kinase is increased in Parkinson disease brain and its inhibition reduces alpha synuclein toxicity. |
| Q88088736 | Adsorption and decontamination of α-synuclein from medically and environmentally-relevant surfaces |
| Q51732455 | Alpha-synuclein aggregates activate calcium pump SERCA leading to calcium dysregulation. |
| Q38582573 | Alpha-synuclein propagation: New insights from animal models |
| Q28082548 | Alpha-synuclein spreading in Parkinson's disease |
| Q33646206 | Amplification of distinct α-synuclein fibril conformers through protein misfolding cyclic amplification. |
| Q37053806 | An Efficient Procedure for Removal and Inactivation of Alpha-Synuclein Assemblies from Laboratory Materials |
| Q36967702 | Anti-ganglioside antibodies are removed from circulation in mice by neuronal endocytosis |
| Q64996446 | Assessment of the efficacy of different procedures that remove and disassemble alpha-synuclein, tau and A-beta fibrils from laboratory material and surfaces. |
| Q89767194 | Autonomic ganglionic injection of α-synuclein fibrils as a model of pure autonomic failure α-synucleinopathy |
| Q36373170 | Bent out of shape: α-Synuclein misfolding and the convergence of pathogenic pathways in Parkinson's disease. |
| Q91705054 | Biological links between traumatic brain injury and Parkinson's disease |
| Q50696857 | Bioluminescence Imaging of Neuroinflammation in Transgenic Mice After Peripheral Inoculation of Alpha-Synuclein Fibrils |
| Q88673114 | Cellular mechanisms responsible for cell-to-cell spreading of prions |
| Q64949212 | Changes in proteome solubility indicate widespread proteostatic disruption in mouse models of neurodegenerative disease. |
| Q64266885 | Comparative analyses of the in vivo induction and transmission of α-synuclein pathology in transgenic mice by MSA brain lysate and recombinant α-synuclein fibrils |
| Q47647268 | Comparison of the in vivo induction and transmission of α-synuclein pathology by mutant α-synuclein fibril seeds in transgenic mice |
| Q61799114 | Constipation, deficit in colon contractions and alpha-synuclein inclusions within the colon precede motor abnormalities and neurodegeneration in the central nervous system in a mouse model of alpha-synucleinopathy |
| Q91260403 | Contribution of syndecans to cellular uptake and fibrillation of α-synuclein and tau |
| Q42069393 | Decontamination of medical devices from pathological amyloid-β-, tau- and α-synuclein aggregates |
| Q92351741 | Desmin forms toxic, seeding-competent amyloid aggregates that persist in muscle fibers |
| Q52575324 | Detection of alpha-synuclein conformational variants from gastro-intestinal biopsy tissue as a potential biomarker for Parkinson's disease. |
| Q55003043 | Differential induction of mutant SOD1 misfolding and aggregation by tau and α-synuclein pathology. |
| Q48019506 | Distinct α-Synuclein strains and implications for heterogeneity among α-Synucleinopathies |
| Q36063245 | Distribution of α-synuclein in the spinal cord and dorsal root ganglia in an autopsy cohort of elderly persons |
| Q92135614 | Diverse Misfolded Conformational Strains and Cross-seeding of Misfolded Proteins Implicated in Neurodegenerative Diseases |
| Q26770060 | Dynamic structural flexibility of α-synuclein |
| Q47284348 | Editorial: Pathogenic templating proteins in Neurodegenerative Disease. |
| Q97527876 | Erythrocytic α-synuclein contained in microvesicles regulates astrocytic glutamate homeostasis: a new perspective on Parkinson's disease pathogenesis |
| Q93118103 | Evidence for bidirectional and trans-synaptic parasympathetic and sympathetic propagation of alpha-synuclein in rats |
| Q26782028 | Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism |
| Q60810349 | Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation |
| Q98504531 | Expanding spectrum of prion diseases |
| Q90632844 | Fatty Acid Binding Protein 3 Enhances the Spreading and Toxicity of α-Synuclein in Mouse Brain |
| Q89919455 | Generation and Characterization of Novel Monoclonal Antibodies Targeting p62/sequestosome-1 Across Human Neurodegenerative Diseases |
| Q26851153 | Glia and alpha-synuclein in neurodegeneration: A complex interaction |
| Q26769620 | Gut Feelings About α-Synuclein in Gastrointestinal Biopsies: Biomarker in the Making? |
| Q38852629 | How strong is the evidence that Parkinson's disease is a prion disorder? |
| Q36607413 | Induction of de novo α-synuclein fibrillization in a neuronal model for Parkinson's disease |
| Q55305758 | Induction of the Immunoproteasome Subunit Lmp7 Links Proteostasis and Immunity in α-Synuclein Aggregation Disorders. |
| Q37555992 | Inflammatory pre-conditioning restricts the seeded induction of α-synuclein pathology in wild type mice |
| Q33735667 | Intrastriatal injection of α-synuclein can lead to widespread synucleinopathy independent of neuroanatomic connectivity |
| Q59796184 | Investigating the neuroprotective effect of AAV-mediated β-synuclein overexpression in a transgenic model of synucleinopathy |
| Q38268519 | Invited review: Prion-like transmission and spreading of tau pathology |
| Q92698886 | Linking the Endoplasmic Reticulum to Parkinson's Disease and Alpha-Synucleinopathy |
| Q64866037 | Localized Induction of Wild-Type and Mutant Alpha-Synuclein Aggregation Reveals Propagation along Neuroanatomical Tracts |
| Q51767457 | Locomotor differences in mice expressing wild-type human α-synuclein |
| Q46412176 | MSA prions exhibit remarkable stability and resistance to inactivation |
| Q92309827 | Manganese promotes the aggregation and prion-like cell-to-cell exosomal transmission of α-synuclein |
| Q64969037 | Mechanisms of protein toxicity in neurodegenerative diseases. |
| Q37592662 | Metal Dyshomeostasis and Their Pathological Role in Prion and Prion-Like Diseases: The Basis for a Nutritional Approach |
| Q64119886 | Microbiome, Parkinson's Disease and Molecular Mimicry |
| Q90298596 | Modeling α-Synuclein Propagation with Preformed Fibril Injections |
| Q38286574 | Models of α-synuclein aggregation in Parkinson's disease |
| Q30817400 | Neuroinvasion of α-Synuclein Prionoids after Intraperitoneal and Intraglossal Inoculation. |
| Q42062219 | New α- and γ-synuclein immunopathological lesions in human brain |
| Q40869024 | Non-prion-type transmission in A53T α-synuclein transgenic mice: a normal component of spinal homogenates from naïve non-transgenic mice induces robust α-synuclein pathology |
| Q37160673 | Novel antibodies to phosphorylated α-synuclein serine 129 and NFL serine 473 demonstrate the close molecular homology of these epitopes |
| Q38794219 | Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases. |
| Q92963280 | Oral and intravenous transmission of α-synuclein fibrils to mice |
| Q92128984 | Organotypic slice culture model demonstrates inter-neuronal spreading of alpha-synuclein aggregates |
| Q26798897 | Oxidative stress and Parkinson's disease |
| Q36639646 | Parkinson disease and progressive supranuclear palsy: protein expression in skin. |
| Q97066892 | Parkinson's Disease and the Gut: Future Perspectives for Early Diagnosis |
| Q38697396 | Parkinson's disease and prion disease: Straining the comparison |
| Q28080503 | Parkinson's disease: animal models and dopaminergic cell vulnerability |
| Q64091665 | Pathogenic alpha-synuclein aggregates preferentially bind to mitochondria and affect cellular respiration |
| Q38928728 | Pathogenic mechanisms of prion protein, amyloid-β and α-synuclein misfolding: the prion concept and neurotoxicity of protein oligomers. |
| Q61807052 | Peripheral Inflammation Regulates CNS Immune Surveillance Through the Recruitment of Inflammatory Monocytes Upon Systemic α-Synuclein Administration |
| Q57458019 | Physiological carboxy-truncation of α-synuclein potentiates the prion-like formation of pathological inclusions |
| Q64100766 | Plasma -synuclein levels are increased in patients with obstructive sleep apnea syndrome |
| Q52718516 | Potent prion-like behaviors of pathogenic α-synuclein and evaluation of inactivation methods. |
| Q38942540 | Potential Pathways of Abnormal Tau and α-Synuclein Dissemination in Sporadic Alzheimer's and Parkinson's Diseases |
| Q40087267 | Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles |
| Q50908801 | Prion Diseases. |
| Q64096411 | Prion and Prion-Like Protein Strains: Deciphering the Molecular Basis of Heterogeneity in Neurodegeneration |
| Q91637190 | Prion-Like Mechanisms in Parkinson's Disease |
| Q36321556 | Prion-like propagation of human brain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synuclein |
| Q36426422 | Prion-like propagation of mutant SOD1 misfolding and motor neuron disease spread along neuroanatomical pathways |
| Q64867396 | Prion-like propagation of pathology in Parkinson disease |
| Q48090188 | Prion-like transmission of α-synuclein pathology in the context of an NFL null background |
| Q35151971 | Progressive aggregation of alpha-synuclein and selective degeneration of lewy inclusion-bearing neurons in a mouse model of parkinsonism |
| Q91786497 | Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases |
| Q27322513 | Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies |
| Q64238991 | Propagation of α-Synuclein Strains within Human Reconstructed Neuronal Network |
| Q38303579 | Protein Transmission, Seeding and Degradation: Key Steps for α-Synuclein Prion-Like Propagation |
| Q90591155 | Protein transmission in neurodegenerative disease |
| Q48619578 | Proteolysis of α-synuclein fibrils in the lysosomal pathway limits induction of inclusion pathology |
| Q47665674 | Prying into the Prion Hypothesis for Parkinson's Disease |
| Q38667942 | Review: Sporadic Parkinson's disease: development and distribution of α-synuclein pathology |
| Q38669105 | Review: Spreading the word: precise animal models and validated methods are vital when evaluating prion-like behaviour of alpha-synuclein |
| Q37560714 | Robust Central Nervous System Pathology in Transgenic Mice following Peripheral Injection of α-Synuclein Fibrils |
| Q46217157 | Rotenone and elevated extracellular potassium concentration induce cell-specific fibrillation of α-synuclein in axons of cholinergic enteric neurons in the guinea-pig ileum. |
| Q64866693 | Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial |
| Q38652662 | Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology |
| Q47361450 | Spread of aggregates after olfactory bulb injection of α-synuclein fibrils is associated with early neuronal loss and is reduced long term |
| Q28082279 | Spreading of pathology in neurodegenerative diseases: a focus on human studies |
| Q64088424 | Spreading of α-Synuclein and Tau: A Systematic Comparison of the Mechanisms Involved |
| Q64229161 | Stereotaxic Targeting of Alpha-Synuclein Pathology in Mouse Brain Using Preformed Fibrils |
| Q36796130 | Structural and functional properties of prefibrillar α-synuclein oligomers |
| Q35903351 | Studies of lipopolysaccharide effects on the induction of α-synuclein pathology by exogenous fibrils in transgenic mice |
| Q39035488 | The Prion-Like Behavior of Assembled Tau in Transgenic Mice |
| Q51284194 | The Transcellular Propagation and Intracellular Trafficking of α-Synuclein. |
| Q53841253 | The concept of alpha-synuclein as a prion-like protein: ten years after |
| Q90408376 | The expression level of alpha-synuclein in different neuronal populations is the primary determinant of its prion-like seeding |
| Q39151589 | The prion model for progression and diversity of neurodegenerative diseases |
| Q64785696 | The usual suspects, dopamine and alpha-synuclein, conspire to cause neurodegeneration |
| Q35726772 | Total and Proteinase K-Resistant α-Synuclein Levels in Erythrocytes, Determined by their Ability to Bind Phospholipids, Associate with Parkinson's Disease |
| Q30392912 | Total α-synuclein levels in human blood cells, CSF, and saliva determined by a lipid-ELISA. |
| Q41109426 | Transmission of α-synuclein-containing erythrocyte-derived extracellular vesicles across the blood-brain barrier via adsorptive mediated transcytosis: another mechanism for initiation and progression of Parkinson's disease? |
| Q46252338 | Vertebrate food products as a potential source of prion-like α-synuclein. |
| Q59810225 | What is the Evidence That Parkinson's Disease is a Prion Disorder, Which Originates in the Gut? |
| Q37197984 | Widespread transneuronal propagation of α-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson's disease |
| Q38753941 | ɑ-Synuclein strains and the variable pathologies of synucleinopathies |
| Q51162977 | Α-synuclein induces microglial cell migration through stimulating HIF-1α accumulation |
| Q90629573 | α-Synuclein filaments from transgenic mouse and human synucleinopathy-containing brains are major seed-competent species |
| Q39256792 | α-Synuclein nonhuman primate models of Parkinson's disease |
| Q41681113 | α-Synuclein strains cause distinct synucleinopathies after local and systemic administration |
| Q38915762 | α-Synuclein: Experimental Pathology |
| Q36148374 | α-synuclein assemblies sequester neuronal α3-Na+/K+-ATPase and impair Na+ gradient |
| Q39124651 | α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies |
Search more.